tradingkey.logo
tradingkey.logo

HeartSciences Inc

HSCS
2.270USD
-0.040-1.73%
Close 03/30, 16:00ETQuotes delayed by 15 min
182.56KMarket Cap
LossP/E TTM

HeartSciences Inc

2.270
-0.040-1.73%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of HeartSciences Inc

Currency: USD Updated: 2026-03-27

Key Insights

HeartSciences Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 138 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.00.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

HeartSciences Inc's Score

Industry at a Glance

Industry Ranking
138 / 208
Overall Ranking
376 / 4542
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

HeartSciences Inc Highlights

StrengthsRisks
HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
Growing
The company is in a growing phase, with the latest annual income totaling USD 4.35K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 4.35K.
Undervalued
The company’s latest PE is -0.50, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 181.19K shares, increasing 30.01% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 18.56K shares of this stock.

Analyst Rating

Based on 2 analysts
Buy
Current Rating
10.000
Target Price
+332.90%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of HeartSciences Inc is 5.77, ranking 186 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is low.

Score

Industry at a Glance

Previous score
5.77
Change
0

Financials

7.54

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

7.78

Operational Efficiency

2.64

Growth Potential

3.77

Shareholder Returns

7.12

HeartSciences Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of HeartSciences Inc is 5.61, ranking 181 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -0.50, which is -99.74% below the recent high of -0.00 and -893.86% above the recent low of -4.99.

Score

Industry at a Glance

Previous score
5.61
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 138/208
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of HeartSciences Inc is 8.00, ranking 61 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 13.50, with a high of 15.00 and a low of 12.00.

Score

Industry at a Glance

Previous score
8.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts
Buy
Current Rating
10.000
Target Price
+344.44%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

92
Total
4
Median
7
Average
Company name
Ratings
Analysts
HeartSciences Inc
HSCS
2
Boston Scientific Corp
BSX
37
Intuitive Surgical Inc
ISRG
36
Edwards Lifesciences Corp
EW
34
Veeva Systems Inc
VEEV
33
Thermo Fisher Scientific Inc
TMO
29
1
2
3
...
19

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of HeartSciences Inc is 2.54, ranking 201 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 2.62 and the support level at 2.05, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
2.50
Change
0.04

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.037
Sell
RSI(14)
27.478
Sell
STOCH(KDJ)(9,3,3)
5.683
Oversold
ATR(14)
0.154
Low Volatility
CCI(14)
-200.868
Oversold
Williams %R
94.737
Oversold
TRIX(12,20)
-0.691
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
2.386
Sell
MA10
2.494
Sell
MA20
2.556
Sell
MA50
2.893
Sell
MA100
2.842
Sell
MA200
3.221
Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of HeartSciences Inc is 3.00, ranking 135 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 5.70%, representing a quarter-over-quarter increase of 61.17%. The largest institutional shareholder is The Vanguard, holding a total of 18.56K shares, representing 0.58% of shares outstanding, with 228.65% increase in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
DRW Securities, LLC
83.61K
--
Simpson (Andrew)
74.38K
+1597.44%
Icahn School of Medicine at Mount Sinai
48.55K
--
Matthews (John H)
39.73K
--
TFB Advisors LLC
29.74K
--
Geode Capital Management, L.L.C.
12.78K
+10.16%
Astoria Strategic Wealth, Inc.
18.93K
--
The Vanguard Group, Inc.
Star Investors
18.56K
+1308.96%
Tower Research Capital LLC
172.00
-74.14%
1
2

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of HeartSciences Inc is 2.27, ranking 160 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 2.48. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Score

Industry at a Glance

Previous score
2.27
Change
0
Beta vs S&P 500 index
2.51
VaR
--
240-Day Maximum Drawdown
+61.78%
240-Day Volatility
+101.57%

Return

Best Daily Return
60 days
+13.75%
120 days
+13.75%
5 years
--
Worst Daily Return
60 days
-7.86%
120 days
-18.90%
5 years
--
Sharpe Ratio
60 days
-2.05
120 days
-1.04
5 years
--

Risk Assessment

Maximum Drawdown
240 days
+61.78%
3 years
+98.26%
5 years
--
Return-to-Drawdown Ratio
240 days
-0.56
3 years
-0.33
5 years
--
Skewness
240 days
+0.48
3 years
+0.94
5 years
--

Volatility

Realised Volatility
240 days
+101.57%
5 years
--
Standardised True Range
240 days
+11.91%
5 years
--
Downside Risk-Adjusted Return
120 days
-171.19%
240 days
-171.19%
Maximum Daily Upside Volatility
60 days
+55.98%
Maximum Daily Downside Volatility
60 days
+45.21%

Liquidity

Average Turnover Rate
60 days
+11.73%
120 days
+7.03%
5 years
--
Turnover Deviation
20 days
-99.30%
60 days
-99.22%
120 days
-99.53%

Peer Comparison

Healthcare Equipment & Supplies
HeartSciences Inc
HeartSciences Inc
HSCS
4.92 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc
TMO
8.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bioventus Inc
Bioventus Inc
BVS
8.28 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
Anika Therapeutics Inc
ANIK
8.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
Lantheus Holdings Inc
LNTH
8.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
Edwards Lifesciences Corp
EW
8.05 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI